Evidence-Based Prescribing of Statins: A Developing World Perspective
Open Access
- 21 February 2006
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (3) , e50
- https://doi.org/10.1371/journal.pmed.0030050
Abstract
Although statins reduce the incidence of cardiovascular disease, they are expensive. How should trial evidence on statins be applied to a resource-poor setting?Keywords
This publication has 61 references indexed in Scilit:
- Dangers of rosuvastatin identified before and after FDA approvalThe Lancet, 2004
- Optimal low-density lipoprotein is 50 to 70 mg/dlJournal of the American College of Cardiology, 2004
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?Published by Oxford University Press (OUP) ,2001
- Efficacy of three statins at lower maintenance dosesClinical Therapeutics, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countriesThe American Journal of Cardiology, 1986